Give Patients With ALS a Chance
Help Slow the Loss of Physical Function
aAs measured by total score on the ALS Functional Rating Scale-Revised (ALSFRS-R) in a 24-week study of 137 participants.1 Individual results may vary.
in the US as of December 20212
in the US as of December 20212
for at least 6 months2
Based on data collected from
In the pivotal clinical trial for

less change in ALSFRS-R scores from baseline vs placebo at 24 weeks.1
Eligible Patients pay as little as $0 per infusion with Commercial Insurance
Learn about our Out-of-Pocket Assistance Program for patients with commercial insurance
There is a $20,000 maximum
program benefit per calendar year per patient.
Learn how veterans with ALS can get started through the VHA
bSubject to National Prior Authorization criteria.
-
References:
- RADICAVA Prescribing Information. Jersey City, NJ: Mitsubishi Tanabe Pharma America, Inc.; 2021.
- Data on file. Mitsubishi Tanabe Pharma America, Inc.